ercc1 survivin在非小细胞肺癌中的表达及其与顺铂化疗敏感性 预后的相关研究word格式论文.docxVIP

犯、远处转移、大血管侵犯等临床病理特征无关；而 Survivin 蛋白表达阴性组有效率（44.4%）明显高于 Survivin 表达阳性组有效率（19.3%）（P=0.009）；Survivin 蛋白表达阴性组 OS、TTP 分别为 407 天、200 天明显长于 Survivin 表达阳性组 354 天、187 天，但无统计学差异（P＞0.05）。ERCC1 和 Survivin 蛋白表达共同阴性 组有效率（46.4%）明显高于共同阳性组有效率（16.7%），两者表达共同阴性组 的 OS、TTP 分别为 399 天、202 天长于共同阳性组 280 天、152 天，但无统计学 差异（P＞0.05）。Cox 比例风险回归多因素分析显示 ERCC1 蛋白表达水平是影响 预后的独立因素，ERCC1 蛋白表达阴性组较阳性组生存期长，（P=0.045），相对 危险度 0.42，95%的可信区间（0.180，0.981）。在 93 例 NSCLC 患者中，ERCC1 蛋白表达阳性 56 例，其中 Survivin 蛋白表达阳性 48 例；ERCC1 蛋白表达阴性 37 例，其中 Survivin 蛋白表达阴性 28 例，ERCC1 和 Survivin 表达呈正相关（r=0.617， P＜0.01）。结论：1、ERCC1 、Survivin 阳性表达提示 DDP 化疗耐药，阴性表达者能从含 DDP化疗方案中获益。2、ERCC1 表达水平是提示预后的独立因素。【关键词】切除修复交叉互补基因 1，生存素，非小细胞肺癌，顺铂The Expression ERCC1 and Survivin Correlated With Chemotherapy Sensitivity and Prognosis of The Advanced NSCLC Patients Treated With Cisplatin-based ChemotherapyAbstractObjective: To investigate the expression of ERCC1, Survivin in the advanced NSCLC and analyze the relationship between their expression and response rate, survival of the NSCLC patients.Methods: 1. The resistance of A549/DDP cells was meassured by MTT assay. 2. The expression of ERCC1 and Survivin mRNA was measured by RT-PCR in A549 and A549/DDP cells respectively. The relation to their expression and cisplatin resistance was anlyzed. 3. From January 2005 to August 2008, 93 pathologically confirmed stageⅢ/Ⅳ NSCLC patients who had received cisplatin-based chemotherapy were incluedImmunohistochemical staining was used to detected the protein of ERCC1 and Survivin in paraffin-embedded samples obtained from bronchoscopy tumour biopsies or lung puncture tumour biopsies. Their expression and clinical characteristic, tumour response, survival were analyzed retrospectively.Results: 1 The average IC50 for DDP were 6.27μg/ml±0.54μg/ml and 69.99μg/ml±7.84 μg/ml in A549 and A549/DDP respectively. The A549/DDP cell line was 11.16-fold resistant to cisplatin than its parental cell line A549. 2.In the A549/DDP cell line,the expression levels of ERCC1 and Survivi